ABSTRACT
OBJETIVO: Investigar la presencia de las alteraciones citogenéticas conocidas del melanoma de coroides en una serie de pacientes diagnosticados y tratados en nuestra Unidad de Oncología Ocular. También exponemos una revisión de la literatura actual sobre este tema. MÉTODO: Durante dos años se han estudiado muestras procedentes de piezas de enucleación o de resección de melanoma coroideo de un total de 27 pacientes mediante análisis de microsatélites (MSA) para estudio de pérdida de heterocigosidad (LOH) del cromosoma 3 y mediante multiplex-ligation-prove amplification (MLPA) para los cromosomas 1, 3, 6 y 8. RESULTADOS: Entre los casos estudiados, 20 mostraron como mínimo una de las alteraciones citogenéticas que se buscaban, 11 LOH del cromosoma 3 (44%), 8 ganancias del cromosoma 6 p (30%), 8 ganancias en cromosoma 8 (30%) y 7 pérdidas totales o parciales del cromosoma 1 (26%). CONCLUSIONES: Este es el primer estudio citogenético del melanoma de úvea en nuestro país.La presencia y preponderancia de las distintas alteraciones citogenéticas se corresponden con las de las series publicadas en la literatura. El análisis citogenético nos permite conocer mejor el pronóstico vital individualizado. También puede resultar una herramienta valiosa para establecer el protocolo de seguimiento más adecuado y la necesidad de tratamientos adyuvantes en estos pacientes
PURPOSE: To investigate the presence of known cytogenetic alterations of choroidal melanoma in a series of patients diagnosed and treated in our Ocular Oncology Service. A review of the present literature on this topic is also presented. METHODS: Microsatellite analysis (MSA) studies on loss of heterozygosity (LOH) of chromosome 3, as well as multiplex ligation prove amplification (MLPA) on chromosomes 1, 3, 6 and 8, were performed on enucleation or local resection samples obtained from a total of 27 patients, over a 2 year period. RESULTS: Twenty patients showed at least one of the cytogenetic alterations looked for. A total of 11 cases were found that showed LOH of chromosome 3 (44%), 8 gains of chromosome 8 (30%), 8 gains of chromosome 6 p (30%), and 7 partial or total losses of chromosome 1 (26%). CONCLUSIONS: This is the first study on the cytogenetics of choroidal melanoma performed in our country. The results are similar to that published in the literature. Cytogenetic analysis provides more accurate knowledge on a vital individual prognosis. It also may become a valuable tool for establishing the most adequate follow-up regimes, and the need for adjuvant therapies
Subject(s)
Humans , Cytogenetic Analysis/methods , Melanoma/pathology , Choroid Neoplasms/pathology , Uveal Neoplasms/pathology , Microsatellite Repeats , Loss of HeterozygosityABSTRACT
PURPOSE: To investigate the presence of known cytogenetic alterations of choroidal melanoma in a series of patients diagnosed and treated in our Ocular Oncology Service. A review of the present literature on this topic is also presented. METHODS: Microsatellite analysis (MSA) studies on loss of heterozygosity (LOH) of chromosome 3, as well as multiplex ligation prove amplification (MLPA) on chromosomes 1, 3, 6 and 8, were performed on enucleation or local resection samples obtained from a total of 27 patients, over a 2 year period. RESULTS: Twenty patients showed at least one of the cytogenetic alterations looked for. A total of 11 cases were found that showed LOH of chromosome 3 (44%), 8 gains of chromosome 8 (30%), 8 gains of chromosome 6p (30%), and 7 partial or total losses of chromosome 1 (26%). CONCLUSIONS: This is the first study on the cytogenetics of choroidal melanoma performed in our country. The results are similar to that published in the literature. Cytogenetic analysis provides more accurate knowledge on a vital individual prognosis. It also may become a valuable tool for establishing the most adequate follow-up regimes, and the need for adjuvant therapies.
Subject(s)
Choroid Neoplasms/genetics , Chromosome Aberrations , Loss of Heterozygosity , Melanoma/genetics , Microsatellite Repeats , Aged , Aneuploidy , Brachytherapy , Choroid Neoplasms/pathology , Choroid Neoplasms/therapy , Chromosomes, Human/ultrastructure , Eye Enucleation , Female , Humans , Male , Melanoma/pathology , Melanoma/therapy , Middle Aged , Multiplex Polymerase Chain Reaction , Prognosis , Tumor BurdenABSTRACT
Objetivo: Comparar la respuesta a ranibizumab entre pacientes con degeneración macular asociada a la edad con y sin tracción vitreomacular acompañante. Métodos: Nuestro archivo de imágenes de tomografía de coherencia óptica de pacientes con degeneración macular ha sido examinado en busca de imágenes de tracción vitreomacular. Un grupo control fue seleccionado de la misma base de datos para la comparación. La historia clínica de los pacientes fue examinada en busca de datos acerca de la evolución de la agudeza visual y del número de inyecciones intravítreas necesarias para controlar la enfermedad. Resultados: La base de datos estaba formada por 373 ojos. Entre ellos, 18 mostraron imágenes de tracción vitreomacular. La media de seguimiento fue de 20,6 meses (desviación estándar [DE] = 10,6; rango = 10,4-31,7).Los pacientes del grupo de tracción vitreomacular recibieron un promedio de 5,1 inyecciones mientras que un promedio de 4,2 inyecciones fue necesario en los pacientes en el grupo control. La media del cambio en la agudeza visual (tablas ETDRS) fue de -15 letras para el grupo de la tracción vitreomacular, y -4,9 letras para el grupo control. (p = 0,07). Conclusiones: Después del tratamiento con ranibizumab, los pacientes de nuestro estudio con degeneración macular asociada a la edad y tracción vitreomacular coexistente han mostrado tendencia a alcanzar una peor agudeza visual que los pacientes sin este hallazgo. Además, estos pacientes han necesitado un mayor número de inyecciones intravítreas para obtener respuesta clínica. No existen en la literatura actual estudios previos sobre este aspecto (AU)
Purpose: The purpose of the present study is to compare the responses to ranibizumab between wet age-related macular degeneration patients, with and without accompanying vitreomacular traction syndrome. Methods: Our database of optical coherence tomography files was searched for eyes of age-related macular degeneration patients that had been treated with ranibizumab, and that had evidence of vitreomacular traction. A control group was selected from the same database for comparison. The case history of each selected individual was reviewed for data regarding the evolution of visual acuity in that patient, and the number of intravitreal injections that had been required to date. Results: From a database of 373 eyes, clear images of vitreomacular traction were obtained for a total of 18 eyes. The mean follow-up period was 20.6 months (SD = 10.6, range = 10.4-31.7).Patients in the vitreomacular traction group had been given an average of 5.1 injections versus an average of 4.2 injections in patients in the control group. The mean changes in visual acuity (which was measured using ETDRS charts) were -15 letters and -4 letters in the vitreomacular traction and control groups (P=0.07), respectively. Conclusions: After ranibizumab treatment, age-related macular degeneration patients with accompanying vitreomacular traction showed a tendency to have a poorer prognosis in terms of visual acuity than patients without this finding. In addition, higher numbers of intravitreal injections were required to obtain clinical responses in patients with vitreomacular traction (AU)
Subject(s)
Humans , Antibodies, Monoclonal/pharmacokinetics , Wet Macular Degeneration/drug therapy , Aging , Visual Acuity , Treatment OutcomeABSTRACT
PURPOSE: The purpose of the present study is to compare the responses to ranibizumab between wet age-related macular degeneration patients, with and without accompanying vitreomacular traction syndrome. METHODS: Our database of optical coherence tomography files was searched for eyes of age-related macular degeneration patients that had been treated with ranibizumab, and that had evidence of vitreomacular traction. A control group was selected from the same database for comparison. The case history of each selected individual was reviewed for data regarding the evolution of visual acuity in that patient, and the number of intravitreal injections that had been required to date. RESULTS: From a database of 373 eyes, clear images of vitreomacular traction were obtained for a total of 18 eyes. The mean follow-up period was 20.6 months (SD=10.6, range=10.4-31.7). Patients in the vitreomacular traction group had been given an average of 5.1 injections versus an average of 4.2 injections in patients in the control group. The mean changes in visual acuity (which was measured using ETDRS charts) were -15 letters and -4 letters in the vitreomacular traction and control groups (P=.07), respectively. CONCLUSIONS: After ranibizumab treatment, age-related macular degeneration patients with accompanying vitreomacular traction showed a tendency to have a poorer prognosis in terms of visual acuity than patients without this finding. In addition, higher numbers of intravitreal injections were required to obtain clinical responses in patients with vitreomacular traction.
